PATH names Ashley Birkett, PhD as director of Malaria Vaccine Initiative (MVI),

PATH announced the appointment of Ashley Birkett, PhD as director of its Malaria Vaccine Initiative (MVI), which “drives the development of safe and effective vaccines for the fight against malaria.”  Dr. Birkett is a five-year veteran of MVI, and was most recently the program’s deputy director, serving simultaneously as director of research and development (R&D)—the latter a position he has held since joining PATH in 2008. Dr. David C. Kaslow, vice president of product development at PATH, said, “Since 2008, Ashley has contributed significantly to every major R&D initiative at MVI.  His technical expertise, tireless passion, and indomitable leadership make him the ideal person to lead MVI in the exciting journey that lies ahead for malaria vaccine development. I am also pleased that PATH can attract and grow top talent and is able to promote such talent from within the organization.”